BindingDB logo
myBDB logout

44 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28245354 5 Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.EBI Merck& Co.
27816515 143 Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.EBI Merck& Co.
27994755 18 Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.EBI Merck& Co.
27106707 98 Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.EBI Merck Research Laboratories
26762835 342 Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI Icahn School of Medicine at Mount Sinai
25915084 4 Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.EBI Genentech
25998502 8 Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.EBI Acelot, Inc.
25625541 58 Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.EBI Merck & Co., Inc.
25791676 26 Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation.EBI University of Sydney
25415535 118 Inhibitors of c-Jun N-terminal kinases: an update.EBI Eberhard Karls Universit£t T£bingen
25353650 111 Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.EBI Pfizer Inc.
25113930 63 Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.EBI Pfizer Inc.
25219901 19 Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.EBI Technische Universit£t Darmstadt
24354345 34 Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.EBI Genentech
24900590 55 Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.EBI GlaxoSmithKline Pharmaceuticals
24044867 86 Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.EBI Califia Bio Inc.
23768909 50 Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.EBI Novartis Institutes for BioMedical Research
23721803 6 The development of CNS-active LRRK2 inhibitors using property-directed optimisation.EBI The University of Sydney
23454015 54 Triazolopyridazine LRRK2 kinase inhibitors.EBI Elan Pharmaceuticals
23453068 25 Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.EBI Elan Pharmaceuticals
23219325 36 Novel cinnoline-based inhibitors of LRRK2 kinase activity.EBI Elan Pharmaceuticals
24900567 21 Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.EBI Genentech
22863203 1 GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.EBI GlaxoSmithKline Pharmaceuticals R&D
22985112 49 Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.EBI Genentech
22591441 29 Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.EBI Genentech
23066449 3 Brain Penetrant LRRK2 Inhibitor.EBI TBA
24900536 3 Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.EBI TBA
22335897 2 Characterization of TAE684 as a potent LRRK2 kinase inhibitor.EBI University of Dundee
22056746 53 Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.EBI Boehringer-Ingelheim Pharmaceuticals, Inc.
22037378 31824 Comprehensive analysis of kinase inhibitor selectivity.EBI Ambit Biosciences
28408230 13 Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.EBI Charles River